+Compare
GRTX
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
135.59M

GRTX Galera Therapeutics Forecast, Technical & Fundamental Analysis

a clinical-stage biotechnology company, which focuses on the prevention of radiation-induced toxicity

Industry Biotechnology
GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for GRTX with price predictions
08:00 PM EDT Jun 01, 2023

GRTX sees its Stochastic Oscillator recovers from oversold territory

On May 31, 2023, the Stochastic Oscillator for GRTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 39 instances where the indicator left the oversold zone. In of the 39 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 02, 2023. You may want to consider a long position or call options on GRTX as a result. In of 58 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GRTX advanced for three days, in of 189 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 111 cases where GRTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GRTX moved out of overbought territory on May 17, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for GRTX turned negative on May 17, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GRTX broke above its upper Bollinger Band on May 05, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (25.045). P/E Ratio (0.000) is within average values for comparable stocks, (123.096). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.331). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (307.081).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.11B. The market cap for tickers in the group ranges from 365 to 353.84B. NONOF holds the highest valuation in this group at 353.84B. The lowest valued company is CLAZF at 365.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 40%, and the average quarterly price growth was 52%. EFTR experienced the highest price growth at 77%, while BLCM experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 54
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

GRTX is expected to report earnings to fall 22.84% to -38 cents per share on August 14

Galera Therapeutics GRTX Stock Earnings Reports
Q2'23
Est.
$-0.39
Q1'23
Missed
by $0.12
Q4'22
Missed
by $0.07
Q3'22
Missed
by $0.08
Q2'22
Missed
by $0.05
The last earnings report on May 11 showed earnings per share of -50 cents, missing the estimate of -38 cents. With 366.44K shares outstanding, the current market capitalization sits at 135.59M.
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company, which focuses on the prevention of radiation-induced toxicity

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
P.O. Box 134
Phone
+1 610 725-1500
Employees
31
Web
https://www.galeratx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FVADX53.972.16
+4.17%
Franklin Small Cap Value Adv
AAERX17.820.22
+1.25%
American Beacon International Eq R6
SBHSX10.010.12
+1.21%
Segall Bryant & Hamill Intl Sm Cp Ret
INDSX16.59N/A
N/A
ALPS/Kotak India ESG II
HLXCX10.88N/A
N/A
Harding Loevner Emer Mkt ex Chn Instl

GRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRTX has been loosely correlated with FATE. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if GRTX jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRTX
1D Price
Change %
GRTX100%
N/A
FATE - GRTX
34%
Loosely correlated
+3.55%
AMRN - GRTX
33%
Poorly correlated
+5.79%
AXON - GRTX
32%
Poorly correlated
+0.58%
ISEE - GRTX
31%
Poorly correlated
+0.64%
BCAB - GRTX
29%
Poorly correlated
+4.52%
More